SCHEMBL6324072

SCHEMBL6324072

CC(CS)NS(=O)(=O)c1ccc(Br)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.53
MMP1 P03956 7/20 0.53
MMP9 P14780 7/20 0.53
MMP13 P45452 7/20 0.53
MMP3 P08254 6/20 0.53
MMP7 P09237 6/20 0.53
CA12 O43570 2/20 0.50
CA9 Q16790 2/20 0.50
MMP14 P50281 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA2 P00918 2/20 0.49
ALDH1A1 P00352 2/20 0.49
TSHR P16473 1/20 0.49
CA1 P00915 1/20 0.47
MMP8 P22894 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324074 1.00 MMP2 (0.53) MMP2MMP1MMP9MMP13MMP3
SCHEMBL6323465 0.84 CA2 (0.68) MMP2MMP1MMP9MMP13MMP3
SCHEMBL6323466 0.84 CA2 (0.68) MMP2MMP1MMP9MMP13MMP3
SCHEMBL13507008 0.84 MMP2 (0.55) MMP2MMP1MMP9MMP13MMP3
SCHEMBL6321461 0.83 MMP2 (0.56) MMP2MMP1MMP9MMP13MMP3
SCHEMBL6323690 0.83 CA2 (0.53) MMP2MMP1MMP9MMP13MMP3
SCHEMBL6326224 0.83 NR3C1 (0.51) CA12CA9CA2ALDH1A1TSHR
SCHEMBL6329763 0.83 CA2 (0.54) MMP2MMP1MMP9MMP13MMP3
SCHEMBL6320955 0.83 CA2 (0.53) MMP2MMP1MMP9MMP13CA12
SCHEMBL6329758 0.83 CA2 (0.54) MMP2MMP1MMP9MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 MMP2 26/4885MMP1 13/4885MMP9 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.